Phase 3 Prostate Cancer Trial, Recruiting NCT06563388 Sponsor: Roswell Park Cancer Institute Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT06563388
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 1 year of age or older
  • You are willing to give your consent to participate in the study
  • You are well enough to carry out some daily activities (your doctor can confirm this based on your overall health score)
  • Your doctor expects you to live for more than 6 months
  • For parts 1–3 of the trial: you have been diagnosed with lung, prostate, or colorectal cancer that has spread to other parts of the body (shown on scans), with between 1 and 10 sites of spread, and this is a new metastatic diagnosis
  • For part 4 of the trial: you have any type of cancer that has spread, including blood cancers if they have been confirmed by biopsy and are being considered for salvage radiotherapy; you may have 1–10 sites of spread, or limited new growth in 5 or fewer sites
  • Your cancer has been restaged (re-evaluated with scans) within roughly the past 3 months before joining the trial
  • If you are receiving radiation to the chest area, your doctor must confirm there are no signs of a scarring lung condition on your scans — or you must be assessed by a lung specialist first (confirm with trial site)
  • If you could become pregnant, you must agree to use appropriate birth control during the study, and must tell your doctor immediately if you become pregnant or suspect pregnancy

Who may not be able to join:

  • You have no available standard drug/medication treatment options, or you are refusing standard treatment alongside the trial
  • You have had chemotherapy or radiation therapy within the past 3 weeks (or 6 weeks for certain specific chemotherapy drugs) before joining, or you are still experiencing side effects from previous treatment
  • You have serious health conditions that would make radiotherapy unsafe — for example, a scarring lung disease if chest radiation is needed, Crohn's disease or ulcerative colitis if the bowel area would be treated, or certain immune/connective tissue diseases like lupus or scleroderma
  • You have liver metastases (cancer spread to the liver) along with moderate or severe liver problems (confirm with trial site)
  • You have previously had radiation treatment in an area that would significantly overlap with the new radiation planned — though prior radiation is not automatically disqualifying (confirm with trial site)
  • You have a build-up of cancerous fluid around your lungs
  • Not all of your cancer sites can be treated with radiation
  • Your cancer has spread into the digestive tract (such as the esophagus, stomach, or bowel) or into the skin
  • You have been diagnosed with cancer that has spread to the brain
  • You have an uncontrolled serious illness, such as an active infection, heart failure, unstable chest pain, irregular heartbeat, or a mental health or personal situation that would make it hard to follow the study requirements
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Anurag Singh, MD, Roswell Park Comprehensive Cancer Center

Phone: 1-800-767-9355

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Roswell Park Cancer Institute
Registry
ClinicalTrials.gov
Start date
18 September 2024
Est. completion
18 September 2032

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Overall Survival - Trial 1 and 2; Androgen DeprivationTherapy (ADT)-free survival - Trial 3

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov